The healthcare industry in the Middle East: Challenges and opportunities

As we present some of the leading figures in the sector in this special issue of Arabian Business, we explore the current state of the healthcare industry in the Middle East, the challenges it encounters, and the opportunities for improvement.

Healthcare landscape in the Middle East

The Middle East is a diverse region comprising countries with varying economic development, healthcare systems, and healthcare infrastructure. Countries like the UAE, Saudi Arabia, Qatar, and Kuwait have made substantial investments in their healthcare sectors, leading to advancements in medical technology, facilities, and expertise. On the other hand, some other nations struggle with inadequate resources, insufficient funding, and disparities in healthcare access.

Challenges faced by the healthcare industry

Infrastructure and resources: Many Middle Eastern countries face challenges related to healthcare infrastructure. While some nations have well-equipped and modern medical facilities, others have limited resources and lack the necessary infrastructure to meet the growing healthcare demands of their populations.

Human resources and brain drain: There is a significant dependence on expatriate healthcare professionals in some Middle Eastern countries, which leads to brain drain from the region’s own talent pool. This reliance can lead to skill shortages and hinder the development of local expertise in healthcare.

Lifestyle-related diseases: The prevalence of lifestyle-related diseases, such as obesity, diabetes, and cardiovascular diseases, has been on the rise in the Middle East. Rapid urbanisation, sedentary lifestyles, and changes in dietary habits contribute to this trend, placing an increased burden on healthcare systems.

Healthcare financing: Healthcare financing is a significant challenge in the region. While some countries have robust healthcare financing systems, others face financial constraints and struggle to provide universal healthcare coverage to their citizens.

Quality and accessibility: There are disparities in healthcare access and quality within and between countries in the Middle East. Rural areas often have limited access to healthcare facilities, and the quality of services can vary significantly.

Opportunities for improvement

Investment in healthcare infrastructure: Governments and private entities in the Middle East should continue to invest in healthcare infrastructure to enhance medical facilities, research centres, and hospitals. Increased funding can help modernise existing infrastructure and build new facilities where needed.

Capacity building and talent retention: To reduce the dependence on foreign healthcare professionals, the region must focus on capacity building and invest in local talent. This includes providing advanced medical education and training opportunities to attract and retain skilled healthcare practitioners.

Preventive healthcare initiatives: Prioritising preventive healthcare initiatives can help reduce the prevalence of lifestyle-related diseases. Governments can implement awareness campaigns, promote healthier lifestyles, and improve nutrition education.

Health insurance reforms: Reforms in health insurance systems can improve healthcare access and affordability. Governments can work towards creating comprehensive health insurance schemes that cover a wide range of services for their citizens.

Embracing telemedicine and digital health: The adoption of telemedicine and digital health solutions can enhance healthcare accessibility, especially in remote areas. These technologies can enable remote consultations, improve patient monitoring, and facilitate medical education.

Healthcare Visionaries 2023	Healthcare Visionaries 2023
1. Shaista Asif	20. Sherine Helmy
2. John Sunil	21. Ashish Koshy
3. Naser Al Yammahi	23. Mohammed Hassan Amin
4. Pelin Incesu	24 Ismail Shehada
5. Hady El Khoury	25. Zaid S. Al Khayyat
6. Alisha Moopen	26. Amin Magrabi
7. Akbar Moideen Thumbay	28. Lennaert Rijken
8. Dr. Sana Sajan	29. Basel Ziyadeh
9. Dr. Reem Osman	30. Jean-Paul Scheuer
10. Ashraf Mallak	31. Jobilal Vavachan
11. Parmjot Bains	32. Tamer El Sallab
12. Raza Siddiqui	33. John Ireland
13. Dr. Michael Fakih	34. Ole Per Maloy
14. Dr. Ihsan Al Marzooqi	35. Akram Bouchenaki
15. Mana Bin Mansour Almana	36. Alexander Jankuloski
16. Said Darwazah	37. Hasan Al Nowais
17. Dr. Hanan Al Kuwari	38. Dr. Bashar Bizrah
18. Dr. Sulaiman Al Habib	39. Dr. Rami Abadi
19. Ayman Tamer	40. Dr. Sanjay Parashar

Rank: 1
Name: Shaista Asif
Designation: Co-founder and Group COO
Company: PureHealth Group
Country: UAE

Shaista Asif has an impressive career trajectory spanning over two decades, with 17 years in the healthcare industry. In 2006, she co-founded the PureHealth, and has been steering the Group’s growth and development, transforming the Group into the largest healthcare group in the Middle East.

As Group Chief Operating Officer, Shaista’s strategic vision is the driving force behind PureHealth’s continuous innovation, leading the Group’s diverse portfolio which includes hospitals, clinics, laboratories, health insurance, healthcare procurement, and health tech solutions. She has spearheaded large healthcare acquisitions both locally and globally, propelling PureHealth to become the fastest growing and largest healthcare company in the region.

Region’s only integrated platform and largest healthcare group

PureHealth has solidified its position as a pivotal player in the region’s healthcare landscape with an extensive network of over 25 hospitals, 160 laboratories, and more than 100 clinics, supported by over 24,000 dedicated employees.

At the core of PureHealth’s success lies its holistic ecosystem, comprising prominent entities like Abu Dhabi Health Services Company (SEHA), National Health Insurance Company (Daman), Abu Dhabi Stem Cells Centre (ADSCC), Ambulatory Healthcare Services, Yas Clinic Group, Rafed, PureLab, One Health, The Life Corner, Tamouh Healthcare and the Medical Office.

The success doesn’t stop at the Middle East, PureHealth has made significant progress expanding its global reach, including acquisition of stake in Ardent Health Services, the United States’s fourth largest privately held healthcare group, adding to its integrated portfolio more than 200 sites of care, 30 hospitals, over 23,000 employees, which operates across six US states, reflecting PureHealth’s prominent presence in the international market. PureHealth is further looking to expand its international presence through acquisitions and working towards becoming a global player.

PureHealth is on a transformative mission to revolutionise the future of healthcare by shifting its focus from reactive sick care to proactive healthcare. Leveraging its integrated and international network, PureHealth introduces Healthcare in the Cloud, digitising real-time patient data for prompt interventions.

Utilising Artificial Intelligence and Machine Learning, PureHealth engages with the population, by baselining their health through various methods including genome sequencing, to enable people to receive personalised care. Taking healthcare to the edge through wearables and IoT, the eco-system provides continuous monitoring for proactive health management.

This reimagines health spans, challenges traditional life spans, and fuels the next generation of innovation, all aligned with PureHealth’s North Star – Longevity, empowering individuals to lead longer, healthier, and more fulfilling lives, furthermore, shaping a sustainable and healthier future for individuals around the world.

Rank: 2
Name: John Sunil
Designation: CEO
Company: Burjeel Holdings
Country: UAE

With an illustrious legacy spanning nearly two decades, Burjeel Holdings has pioneered a new paradigm of healthcare. In 2007, Dr. Shamsheer Vayalil, its founder and chairman, began with a single hospital in Abu Dhabi and a vision to make quality healthcare and clinical excellence available to everyone.

Since then, Burjeel Holdings has consistently pushed boundaries by harnessing state-of-the-art technology and attracting world-renowned medical talent to deliver high-quality, complex care to people in the UAE and the wider region, through its facilities including its flagship Burjeel Medical City. The group has an unmatched patient offering and a diversified portfolio of 16 hospitals and 24 medical centres across the UAE and Oman.

Burjeel Holdings continues to focus on key areas including oncology, nuclear medicine, orthopedics and spine, women’s care, fetal medicine and pediatric specialties, organ transplant, and bone marrow transplant. As part of its geographic expansion strategy across key markets in the region, the group marked its entry to the Kingdom of Saudi Arabia recently by setting up a network of first-of-its-kind advanced physiotherapy, rehabilitation, and wellness centres.

A new era of leadership

Since 2022, CEO John Sunil’s dynamic leadership has ushered in a new era of healthcare innovation. Sunil has built a history of leadership at Burjeel Holdings, holding the roles of Financial Controller, COO, Regional CEO, and finally, the CEO of Burjeel Holdings.
As the CEO, he creates value for stakeholders by developing and executing strategies for business growth in the long and short term and overcoming business challenges.

Elevating utilization across the Group’s world-class assets and adding to its service portfolio are his areas of focus. Armed with a profound understanding of the healthcare landscape, Sunil continues to lead a team of dedicated healthcare professionals, with a shared focus on advancing patient outcomes and finding innovative solutions to complex healthcare problems.

The shared vision and leadership of both Dr. Shamsheer and Sunil continue to deliver impressive results for patients and the many investors still celebrating its first year as a public company.

Rank: 3
Name: Naser Al Yammahi
Designation: Deputy CEO
Company: Hayat Biotech
Country: UAE

With an illustrious 15-year career, Al Yammahi has successfully navigated both the public and private sectors, establishing himself as a distinguished senior professional specialising in corporate strategy, government affairs, and key partnerships. In his current role at Hayat Biotech, a leading biotechnology and life sciences company in the region, his unwavering commitment lies in advancing the sector’s capabilities.

Al Yammahi’s focus on driving growth, fostering innovation, and forging strategic partnerships, particularly in biotechnology and renewable energies, sets him apart as a visionary leader in the industry. With a strong emphasis on enhancing Hayat Biotech’s capabilities and promoting sustainable practices, he continues to drive transformative change in the business landscape.

Backed by a wealth of experience

Al Yammahi played a pivotal role in the ground-breaking 4Humanity clinical trials, the world’s first Phase III Covid-19 inactive vaccine trials in the UAE and the Middle East, and in the launch of Hayat VAX, the region’s pioneering Covid-19 vaccine.

This demonstrates his skills in forging crucial collaborations with key stakeholders, including Sinopharm, G42, and key government entities as well as his acumen at navigating complex industry initiatives. Al Yammahi also steered the construction of the innovative Hayat Biotech Life Sciences Park, an integrated hub dedicated to research and development and vaccine production. The state-of-the-art facility boasts an output capacity of 200 million vials annually, featuring a fully automated warehouse.

Apart from his accomplishments in biotechnology, Al Yammahi boasts extensive experience in renewable energies, gained during his tenure at Masdar. His leadership was instrumental in overseeing significant projects in Spain and the UK, notably the prestigious $3.3 billion London Array, the world’s largest renewable energy venture.

These projects perfectly align with the UAE’s vision for a greener and more sustainable future. His remarkable contributions in the field of renewable energies have earned him recognition as a forward-thinking leader, dedicated to driving positive change and fostering environmentally conscious practices in the energy sector.

Al Yammahi’s journey exemplifies a visionary leader committed to driving growth, innovation, and strategic partnerships in key sectors, particularly biotechnology and renewable energies. His unwavering dedication to advancing Hayat Biotech capabilities and fostering sustainable practices solidified his position as a respected leader in the industry, driving positive change and propelling the company’s business landscape to new heights.

Rank: 4
Name: Pelin Incesu
Designation: Area Vice President
Company: AstraZeneca
Country: MEA

After qualifying and working as a psychiatrist, Pelin joined AstraZeneca in her native Türkiye in 2000 and since then, has served in several roles and locations. The first Turkish woman to become an AstraZeneca country president which she describes as “a glass ceiling I was proud to break”, Pelin has also served as AstraZeneca vice president of Commercial Strategy internationally.

Since 2020, she has helmed AstraZeneca’s strategy and growth in the Middle East and Africa and in just one year of her appointment to her current role, the company recorded revenues of $1.2 billion from operations in that region. Her current staff of 2,500 individuals are committed towards delivering solutions for patients coping with health issues ranging from cancer to cardiovascular conditions to a range of respiratory and rare diseases.

She also successfully led the company through the uncertainty of the pandemic during the time when AstraZeneca was the leading provider of Covid-19 vaccines to developing countries through the COVAX initiative, including 61 countries in MEA.

Driven by a passion for sustainability

As witnessed at the Dubai EXPO 2020 and COP27 Sharm El-Sheikh, Pelin also steers AstraZeneca’s regional sustainability agenda. In 2023, aligned with the company’s global Ambition Zero Carbon initiative, AstraZeneca will unveil sustainable offices at the Dubai Science Park, as well as take the stage at COP28 UAE to highlight the critical links between climate and health.

Other sustainability initiatives include the recent expansion of AZ Forest, a major global reforestation and biodiversity initiative to Ghana and Rwanda and, recently inaugurating LEED gold-certified offices in Cairo, Egypt.

Pelin is actively working towards achieving gender parity across all levels of the organisation by 2025, leading multiple women’s empowerment initiatives including a Women in Leadership Summit, co-hosted in Riyadh, KSA by AstraZeneca in 2022. Her dedication to promoting an inclusive and diverse workforce is making significant strides towards gender equality, inspiring positive transformation in the corporate world.

Rank: 5
Name: Hady El Khoury
Designation: General manager – MENEAT
Company: GE Healthcare
Country: UAE

With more than 20 years of experience in the industry, El Khoury is a passionate advocate for bringing technology and capabilities to the healthcare sector, supporting patients across markets.

His career began with GE HealthCare in Marketing in France, and he then took on customer-facing roles related to product and service management in Northern Europe. Throughout his tenure, he demonstrated his expertise and leadership, leading to his appointment as the Northern Europe regional services sales manager. Subsequently, he relocated to Dubai, UAE in 2015, highlighting his commitment to supporting the region’s healthcare infrastructure and expanding GE HealthCare’s presence.

Since then, El Khoury has been named to key regional leadership positions, including director of commercial operations, services general manager for emerging markets, and most recently, chief operating officer for Europe Middle East and Africa.

In these roles, he has led growth strategy and supported the expansion of market share in key markets including the Middle East, Northeast Africa, Turkey, and South-Central Asia. El Khoury’s expertise and dedication have been instrumental in enhancing healthcare infrastructure and GE HealthCare’s footprint in these strategic countries.

Backed by an educational foundation that complements his career trajectory, El Khoury graduated from Saint Joseph University of Beirut (Lebanon) in 2002 with a bachelor’s degree in business administration. Additionally, he holds a diploma in Economics from Panthéon-Assas University in Paris and a master’s degree in management and Corporate Finance from SKEMA Business School, also in Nice, France.

Servant leadership and going to “Genba”

According to El Khoury, effective leaders do three things well. First, they clearly lay out strategic direction and priorities for their teams and articulate the steps to achieve them. Second, they create a work environment that fosters openness, transparency, and inclusivity – a place where employees feel safe and empowered to speak up and contribute. Third, they understand the business and are able to remove obstacles in the way of their teams, helping them in achieving their goals.

This leadership approach, which emphasizes being a coach rather than an enforcer speaks to another important aspect of management at GE HealthCare: “servant leadership.” A servant leader approaches their job as being primarily about serving their teams. When employees feel leaders “have their backs,” they are more engaged and motivated and truly give their best, resulting in better business results, and in the case of healthcare, a greater impact on their communities.

GE HealthCare also embraces the principle of Lean, which includes ‘going to Genba,’ wherein leaders spend time with and understand the front-line – be it administrative departments, worksites, or shop floors – to gain first-hand insights and support their teams in making real-world decisions.

GE HealthCare impacts its communities

GE HealthCare has approximately 50,000 employees in over 160 countries around the world. The company is committed to its team and customers, and prioritises fostering an inclusive culture of respect, transparency, and unyielding integrity.

GE HealthCare holds over 11,000 patents globally and is a pioneer in innovative solutions. The company is working to solve the greatest healthcare challenges that patients and clinicians face today, as well as innovate for those they may face in the future. As a leading medical technology and diagnostics innovator, the company enables clinicians to make faster, more informed decisions through intelligent devices, data, analytics, applications, and services, supported by its Edison intelligence platform.

In total, four million imaging, mobile, diagnostic, and monitoring devices worldwide and over two billion patient scans are managed by GE technology annually.

Leadership for the future of healthcare

The company invests $1 billion in R&D annually, with innovation in imaging and lifecare technologies, as well as software and AI. For example, simply by updating their MR machines with new AI-enabled software, exams that formerly took 40 minutes now take only 10 minutes, while delivering better image quality. GE HealthCare is also leveraging AI on a broad scale, across hospitals or multiple clinical sites via GE HealthCare’s Edison cloud platform.

In addition to its technological advancements, the company is actively offering strategic support to health ministries in their pursuit of cost-effective solutions to public health challenges. They assist in developing disease-focused care pathways, particularly in areas like cardiovascular disease and cancer, from prevention and diagnosis to treatment, rehabilitation, chronic disease management, and palliative care. By partnering with health ministries, the company ambitions to make a considerable impact on improving healthcare accessibility and outcomes in the region.

Rank: 6
Name: Alisha Moopen
Designation: Deputy managing director
Company: Aster DM Healthcare
Country: UAE

Having joined the company in 2013, Alisha Moopen has played a pivotal role in spearheading the group’s expansion into new markets, shaping its strategic direction, and driving its continued success. As Deputy Managing Director, she is responsible for Aster’s operations across seven countries, ensuring that the 50,000 patients that the Group serves each day, around 20 million in a year, seamlessly experience Aster’s brand promise of “We’ll Treat You Well”.

Moopen brings an impressive educational background to her role, holding a degree in Chartered Accountancy from the Institute of Chartered Accountants of Scotland (ICAS). Prior to her tenure at Aster DM Healthcare, she gained valuable experience working with Ernst & Young. She furthered her education by obtaining degrees from prestigious institutions, including Finance and Accounting from the University of Michigan and Global Leadership and Public Policy Change from Harvard University.

Beyond her professional achievements, Ms. Alisha Moopen is an advocate for women empowerment and mental health. As the first female Chapter Chair of YPO’s Dubai Chapter, she connects chief executives from over 130 countries, fostering a global network of business leaders. She was also elected to Board of Directors of Sharjah Research Technology and Innovation Park (SRTIP) under the leadership of HH Sheikha Bodour Bint Sultan Bin Mohammed Al Qasimi. Passionate about diversity in the workforce, she firmly believes in embracing the strength of differences.

One of her remarkable contributions at Aster DM Healthcare was the launch of the Women in Leadership program. This initiative empowers talented female employees by providing them with training and growth opportunities, enabling them to take on leadership roles and shatter the glass ceiling at work.

Moopen’s commitment to excellence, her dedication to empowering women, and her efforts in improving mental health initiatives make her a dynamic leader and a driving force behind Aster DM Healthcare’s continued growth and impact in the healthcare industry.

About Aster DM Healthcare

Aster DM Healthcare is one of the largest integrated private healthcare service providers operating in the GCC and India, with a track record of over three decades in delivering compassionate care to patients.

The group offers a comprehensive range of healthcare services, including primary, secondary, tertiary, and quaternary care, through its extensive network of 32 hospitals, 127 Clinics,521 pharmacies (including 257 pharmacies in India operated by Alfaone Retail Pharmacies Private Limited under the brand license from Aster), and 205 labs and patient experience centers across seven countries, including India.

With a dedicated team of over 30,330 staff, including 3,863 doctors and 8,975 nurses, Aster DM Healthcare is committed to its simple yet strong promise to stakeholders: “We’ll treat you well.” The group serves all economic segments in the GCC states through its differentiated healthcare services under the brands “Aster,” “Medcare,” and “Access.”

Recently, Aster DM Healthcare announced the launch of Medcare Royal Hospital in Al Qusais. This new 126-bed medical facility, constructed by Dubai Developments, marks the fourth Medcare Hospital in Dubai and the fifth in the entire UAE, complementing the existing 20 Medcare Medical Centres.

The agreement between Aster DM Healthcare and Dubai Developments was officially signed on 5 July 2023, with plans for the hospital to commence its operations by December 2023. This initiative underscores the group’s commitment to making world-class medical facilities locally available in the country.

Rank: 7
Name: Akbar Moideen Thumbay
Designation: Vice president
Company: Thumbay Healthcare
Country: UAE

Akbar Moideen Thumbay is a highly esteemed professional renowned for his contributions to the healthcare industry. He currently serves as the vice president of Thumbay Healthcare, co-chair of GMU Academic Health System, and a board member of the esteemed Thumbay Group. Established by his father, Dr. Thumbay Moideen, in 1997, the Thumbay Group is a pioneering and diversified business house.

A commitment to exceptional medical services

Praised as a far-sighted healthcare strategist with a global mind-set and a desire to make Thumbay Healthcare a leading innovator in the care delivery, Akbar represents a new generation of sustainability-minded leaders rising in the private healthcare sector. His commitment to accessible and high-quality healthcare has played a crucial role in the growth and success of Thumbay Group’s healthcare operations. During Akbar’s tenure, Thumbay Healthcare grew to be the largest private-academic teaching hospital group in the country, serving patients from as many as 175 countries and conducting more than 80,000 deliveries.

Under his discerning leadership, Thumbay Healthcare has experienced remarkable expansion and development. He has established and managed state-of-the-art clinics, academic hospitals, and medical centres, ensuring comprehensive care and advanced treatment options for patients.

The healthcare arm today operates eight academic hospitals, with facilities that include 800 inpatients beds, 10 family clinics/ medical centres, 5 diagnostic labs, and 46 retail pharmacy outlets and First Drive through Pharmacy options.

He also actively promotes research and development initiatives, fostering a culture of innovation that continuously enhances healthcare practices. From innovative medical equipment to cutting-edge advanced telemedicine solutions, the organisation has continuously invested in the latest technologies that drive innovation and elevate the quality of healthcare services.

Akbar Moideen Thumbay upholds and develops the beloved ideals instilled by his visionary father, Dr. Thumbay Moideen, carrying on his father’s heritage. His greatest assets are his ability to forge strategic alliances with the right companies and brands, as well as his in-depth knowledge of ethics and values-which form the overall Thumbay Healthcare’s mission.

Rank: 8
Name: Dr. Sana Sajan
Designation: Director
Company: American Aesthetics, Danube Group
Country: UAE

Unstoppable wellness trailblazer

Sana Sajan, the driving force behind American Aesthetic Medical Centre in Dubai, embodies a remarkable entrepreneurial streak. Combining her dentistry background with a passion for aesthetics, she fearlessly established the center, offering cutting-edge surgical and non-surgical treatments. Coming from a family with a strong medical background, Sajan’s natural inclination toward medicine led her to pursue dentistry.

However, in 2019, she took a bold step and founded the American Aesthetic Medical Centre in Dubai. This premier establishment offers cutting-edge surgical and non-surgical treatments, encompassing plastic surgery, hair transplantation, cosmetic gynecology, and andrology, as well as advanced laser and skincare procedures.

With a vision to boost individuals’ confidence and enhance their quality of life, the center’s proficient physicians and staff deliver top-tier care within a comfortable and private environment, enabling people to look and feel their best. The center’s commitment to providing outstanding aesthetic results has made it a go-to destination for transformative experiences.

Dubai’s next generation powerhouse

Beyond her medical prowess, Sajan’s eloquence and amicable nature have earned her a prominent place as a sought-after speaker at various forums in media and beyond. Her TED Talk, delivered with captivating grace, showcased her insights into aesthetics and personal empowerment, inspiring countless individuals.

Sajan’s trailblazing journey in the field of aesthetics has propelled her as one of Dubai’s powerful women entrepreneurs. Her success story serves as a beacon of inspiration, breaking barriers and paving the way for other aspiring women to thrive in entrepreneurship.

Using art for philanthropy

In addition to her medical profession, Sajan possesses a remarkable talent for art, which she has been using to support thalassemia patients and raise awareness about the disease in the region. Through independent auctions of her paintings, she donates the proceeds to benefit children with special needs and thalassemia patients. In 2015, she took her support to a larger scale by launching ALIF, the Art Lovers’ International Festival, under the patronage of the Sheikh Sultan Bin Khalifa Al Nahyan Scientific and Humanitarian Foundation.

The festival hosts auctions of calligraphy and contemporary-style portraits, further contributing to thalassemia patients and community-based initiatives. Besides her philanthropic endeavors, Sajan serves as a panel member for IBPC and acts as the brand ambassador and influencer for Dubai Women’s Run. Her passion for Urdu literature has led her to compile a book encompassing the works of over 300 Urdu poetry maestros, from the language’s inception to the present day, including iconic figures like Ghalib and Faiz.

Rank: 9
Name: Dr. Reem Osman
Designation: Regional CEO
Company: Saudi German Health (SGH)
Country: UAE

In her current role since May 2021, Dr. Osman brings over two decades of expertise in the field of healthcare. Under her leadership, SGH has established a firm foothold in Dubai in the Middle East’s burgeoning healthcare industry as well as in the booming medical tourism market.

A medicine graduate from Tishreen University of Medicine in Syria, Dr. Osman went on to earn her master’s degree in business administration as well as a master’s degree in ophthalmology and eye surgery, both from Wollongong University in Sydney, Australia. She also holds a certificate from Harvard Business School in management healthcare delivery.

Founded by the Batterjee family, SGH has 18 facilities across KSA, the UAE, Egypt, Yemen, Morocco, and Pakistan. Part of one of the largest hospitals groups in the MENA region, SGH Dubai offers a broad spectrum of medical services at the international level, including critical care, all types of specialties, as well as sub-specialties.

It also offers one of the largest emergency departments in the private sector. As of Q1 2023, SGH achieved a net profit of $13.3 million in the first quarter, representing a robust 145 percent growth compared to Q1 2022. The results, surpassing peers performance, showcase the extensive work made by the team over the past 12 to 18 months to enhance and improve the group’s operations while expanding the network’s capacity to capitalise on the demand in the kingdom.

Rank: 10
Name: Ashraf Mallak
Designation: Managing director
Company: Merck Sharp & Dohme (MSD) GCC
Country: UAE

Backed by nearly 15 years of experience in MSD, Mallak climbed the career trajectory starting from his role as the regional brand manager MEA from November 2008 to January 2010, eventually to his current role since February 2021. He also holds over 18 years of diversified multi-regional and multifunctional experience at top pharmaceutical MNCs. He earned his Bachelor of Science degree from the University of Jordan and then his MBA from The American University of Dubai.

Established in 1891, MSD is a research biopharmaceutical company that develops viable solutions for vaccines, oncology, infectious diseases, and cardio-metabolic diseases. Steered by a science-led strategy, MSD continues to build a sustainable engine and harness the power of leading-edge science to save and improve lives around the world.

For over 130 years, have brought hope to humanity through the development of important medicines and vaccines. Today, MSD is at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and in animals.

MSD’s Q4 and full-year 2022 results reflect sustained strong revenue growth. The company announced Q4 worldwide sales of $13.8 billion, an increase of 2 percent from Q4 2021. Full-year 2022 worldwide sales were $59.3 billion, an increase of 22 percent from full year 2021. MSD anticipates full-year 2023 worldwide sales to be between $57.2 billion and $58.7 billion.

Rank: 11
Name: Parmjot Bairns
Designation: Gulf Cluster Country Manager
Company: Pfizer
Country: UAE

In her current role since June 2022, Dr. Bains oversees the Pfizer business in the UAE, Bahrain, Kuwait, Oman, Qatar, and Yemen. An experienced global healthcare executive trained in clinical medicine, and experienced in strategy with McKinsey and Company, drug development as a Biotech CEO, and global commercial roles within Pfizer, she is backed by over 19 years of experience across several fields and eight years helming several global roles at Pfizer.

Previously, she was the regional commercial lead APAC for Pfizer’s Hospital Business, where she worked cross-culturally with Pfizer’s global teams across the US and Asia Pacific Region to deliver ground-breaking solutions and innovative products that transform patient outcomes.

With a global presence, Pfizer operates 36 manufacturing sites and distributes its products in over 185 countries, solidifying its reputation as a leading pharmaceutical company. As of 2 May 2023, the company boasts an impressive pipeline of 101 projects, a testament to their dedication to research and development.

Pfizer’s commitment to excellence is evident in their rigorous processes, involving 1,500 scientists overseeing more than 500,000 lab tests and conducting over 36 clinical trials before any product reaches the hands of patients, demonstrating the stringent precautions undertaken by the company. Additionally, Pfizer is pioneering new models for partnerships, embracing creativity, flexibility, and urgency to accelerate the delivery of innovative treatments to patients.

Rank: 12
Name: Raza Siddiqui
Designation: Group CEO
Company: Arabian Healthcare Group (RAK Hospital)
Country: UAE

With a career spanning over 40 years, Siddiqui began as a management trainee at Lupin Laboratories Limited, a leading pharmaceutical firm in India, followed by a role at Ranbaxy Laboratories. He later founded Stancare for Ranbaxy and moved on to helm corporate communications/affairs and strategic planning at Indraprastha Apollo Hospital, New Delhi, India.

During his tenure as director of operations at Belhoul Speciality Hospital, Dubai, on behalf of the Apollo Hospitals Group between 1998 to 2003, Siddiqui played a key role in obtaining Joint Commission International (JCI) accreditation and introduced cardiac surgery programmes to boost medical tourism in the UAE.

He then served as executive director at ETA Star Healthcare, leading the establishment of joint ventures with companies like Trivitron Healthcare. Under Arabian Healthcare Group, he spearheaded the creation of a chain of premium medical/specialty centres across various locations in Ras Al Khaimah.

RAK Hospital, the flagship unit of Arabian Healthcare Group, was launched in 2007 and founded upon the initiative of Sheikh Saud bin Saqr Al Qasimi, Ruler of RAK and Member of the Supreme Council of the UAE. The hospital has firmly secured its place as the new health tourism destination attracting international patients in need of quality healthcare at an affordable price. The hospital has also partnered with ‘Sonnenhof Swiss Health’, a healthcare group from Switzerland leveraging upon the rich Swiss heritage of healthcare and hospitality.

Rank: 13
Name: Dr. Michael Fakih
Designation: CEO
Company: Emirates Hospitals Group|
Country: UAE

In his current role at Emirates Hospitals Group since November 2019, Dr. Fakih boasts over 25 years’ experience and is recognised as a leader in the field of assisted reproduction and is responsible for over 10,000 IVF deliveries. His continuous efforts in innovation of new techniques have made him a pioneer in his field. He is also the medical director of Fakih IVF, UAE and IVF Michigan, USA, as well as the founder of FIRST IVF, Lebanon.

In addition, he is an associate professor at Michigan State University, College of Human Medicine. Fakih IVF is a key IVF programme in Dubai with an in-house embryo genetic diagnosis laboratory (PGD laboratory) and is the only programme in the Middle East to offer cutting-edge blastocyst biopsy followed by fresh embryo transfer, utilising the state-of-the-art micro-array technique.

Emirates Hospitals Group, a leading integrated healthcare provider in the Middle East, operates more than 26 facilities with over 1,500 doctors and medical experts. Their comprehensive services encompass fully serviced hospitals, specialty clinics, urgent care centres, and pharmacies, offering cutting-edge treatment options.

Backed by a multidisciplinary team of skilled doctors with regional and global expertise, the group ensures top-notch care. With strategic acquisitions and expansion efforts, Emirates Hospitals Group continues to reinforce its network by establishing new healthcare facilities across the GCC and other global regions.

Rank: 14
Name: Dr. Ihsan Al Marzooqi
Designation: Co-founder and managing director
Company: Glucare Health
Country: UAE

Leading transformative efforts in diabetes management and metabolic health, Dr. Al Marzooqi specialises in revolutionising the traditional diabetes care model by integrating digital therapeutics. This innovative approach aims to enhance the management and treatment of diabetes, providing patients with more effective and personalised solutions.

Additionally, he is a co-founder of meta[bolic], a hybrid digital therapeutics company dedicated to addressing the global metabolic health crisis. Through this venture, he endeavours to tackle the pressing challenges surrounding metabolic health and improve the overall well-being of individuals worldwide.

With a notable tenure as director and deputy head at Mubadala Healthcare for over a decade, Dr. Al Marzooqi played a pivotal role in shaping the organisation’s healthcare portfolio. His responsibilities encompassed asset management, strategy development, financial performance, business expansion, and operational management.

Furthermore, he served as vice-chairman of the Board of Directors for healthcare institutions including Healthpoint, Imperial College London Diabetes Centre, National Reference Laboratory, Tawam Molecular Imaging Centre, and Capital Health Screening Centre. Glucare Health is a pioneering healthcare company focused on transforming diabetes management through the integration of digital therapeutics into the traditional care model.

Rank: 15
Name: Mana bin Mansour Almana
Designation: Group CEO
Company: Almana Group of Hospitals
Country: KSA

In 2007, Almana began his career at the group, initially appointed as the on-site director of marketing and business development from April 2008 to September 2018. In October 2018, he was appointed to his current role where he is leading the group to achieve its global vision.

Almana holds a bachelor’s degree in Business Administration from King Fahd University of Petroleum and Minerals and a master’s degree in International Business Administration from the University of Surrey, UK. The Almana Group is one of the largest independent, family owned, group of companies in the Gulf region that was established in KSA in 1949 by Sheikh Mohammad Bin Abdullah Almana and grew from its early trading and shipping business to become one of the most diversified and highly regarded business houses in the Gulf region and beyond.

Almana Group, Ebrahim Almana & Brothers, stands as the Eastern Province’s largest Medical Company & Health Care Providers. With a history spanning over seven decades, it has earned its esteemed stature and reputation through exceptional care and a comprehensive array of healthcare services.

Committed to serving the community, Almana Group ensures access to state-of-the-art technology that aligns with international standards in the healthcare industry. With a workforce of 6600 employees; 800 doctors; 1100 total beds; and 8 medical facilities, Almana Group’s Trading Division supplies medical equipment as well as supplies to other national healthcare facilities.

Rank: 16
Name: Said Darwazah
Designation: Executive chairman and CEO
Company: Hikma Pharmaceuticals
Country: Jordan

Said Darwazah’s career at Hikma Pharmaceuticals spans over four decades across key leadership roles. He served as the CEO from July 2007 to February 2018 and has been the executive chairman since May 2014.

Notably, from 1994 to 2003, he held the position of chairman and chief executive of Hikma’s group holding company. Moreover, he also served as the Minister of Health for the Hashemite Kingdom of Jordan from 2003 to 2006. Beyond Hikma, Darwazah is the chairman of Royal Jordanian Airlines and Dead Sea Touristic & Real Estate Investments.

He also serves as Vice Chairman of Capital Bank, Jordan, and is a board member of INSEAD and Dash Ventures Limited. His vast experience and expertise have undoubtedly played a crucial role in shaping Hikma’s success and growth over the years.

Hikma was launched over four decades ago in the MENA region, establishing its branded generic medicines business. Since then, Hikma has experienced remarkable growth with a widespread presence in the US, Canada, the MENA region, and Europe. Hikma’s global reach is facilitated by 32 manufacturing plants and 7 R&D centres and a focus on three main lines of business: injectables, branded, and generics.

A significant accomplishment in 2022 was Hikma moving up the ranks from the fourth to the third largest pharmaceutical company in the MENA region, a testament to the company’s continued growth and success in the industry.

Rank: 17
Name: Dr. Hanan Al Kuwari
Designation: Managing director
Company: Hamad Medical Corporation (HMC)
Country: Qatar

Since 2007, Dr. Al Kuwari holds the distinguished role of the Minister of Public Health for the State of Qatar, overseeing the nation’s healthcare initiatives with dedication and expertise. Additionally, she serves as the managing director of HMC, the primary national provider of hospital care.

Beyond her ministerial and managerial responsibilities, she holds key leadership positions that reflect her commitment to advancing healthcare and research. As the chairperson of the Qatar Biobank Board of Directors and the Academic Health System International Advisory Board, Dr. Al Kuwari plays a crucial role in shaping healthcare strategies for the future.

Furthermore, she is a member of the Hamad Healthcare Quality Institute International Advisory Board and various committees at the Ministry of Public Health. HMC is the primary provider of secondary and tertiary healthcare in Qatar and a leading hospital provider in the Middle East for over four decades.

Managing 12 hospitals, including nine specialist hospitals and three community hospitals, HMC also oversees the National Ambulance Service and home and residential care services. In January 2016, HMC achieved a significant milestone by becoming the first healthcare system worldwide to have all its hospitals accredited by Joint Commission International under the Academic Medical Centre accreditation programme.

Rank: 18
Name: Dr. Sulaiman Al Habib
Designation: Chairman of the board of directors and founder
Company: Dr. Sulaiman Al Habib Medical Services Group (HMG)
Country: KSA

In addition to his current role, Dr. Al Habib also holds the position of chairman of the board of directors of Dr. Sulaiman Al Habib Investment Company. Previously, he served as the head of the department of paediatrics at the Security Forces Hospital in Riyadh from 1988 to 1991.

He earned his bachelor’s degree in Medicine and Surgery from the College of Medicine at King Saud University in Riyadh in 1977 and completed a fellowship in Paediatrics from the British Royal College of Physicians in 1984. As a testament to his commitment and dedication, Dr. Al Habib remains the largest shareholder in the company, owning 40.03 percent of its shares. His visionary leadership has driven HMG to new heights, making it a prominent player in the healthcare industry, with a strong presence and reputation across the Gulf region.

Dr. Sulaiman Al Habib Medical Group is one of KSA’s fastest growing health care organisations. The group runs 22 healthcare facilities in KSA and the UAE. Thanks to its meticulous growth strategy, the group is firmly positioned with market-leading capabilities to meet the anticipated growth in demand for quality healthcare services.

Originally known as the Olaya Medical Complex, established in 1995, today, HMG owns and operates 14 hospitals and seven medical centres across KSA, the UAE, and Bahrain. In 2022, the company achieved remarkable revenues of $2.2 billion and currently holds assets worth $3.4 billion.

Rank: 19
Name: Ayman Tamer
Designation: Group chairman
Company: Tamer Group
Country: KSA

A member of the World Economic Forum Family Business Community for the health industry and the Pharma Committee at Jeddah Chamber of Commerce and Industry, Tamer also sits on the boards of SAJA and Arabio and holds an honorary advisory board membership at Effat University. His achievements are further supported by the favourable regulatory environment in the kingdom.

With a history spanning over 100 years, the Tamer Group traces its roots back to a humble pharmacy and has since flourished into a dynamic family business with a diversified portfolio. Today, the group’s operations encompass various sectors, including healthcare supply, manufacturing, logistics, e-commerce, consumer care, and IT solutions. Employing a workforce of 4,000 individuals, the Tamer Group has emerged as a prominent player in multiple industries, delivering a wide array of medical, pharmaceutical, and nutrition products and services not only in KSA but also across the broader MENA region.

Driven by an unwavering commitment to personal wellness and public health, the group provides a diverse range of products and services that promote the well-being of individuals and communities. The group’s impact on the healthcare landscape and dedication to service excellence reinforce their status as a leading force in the advancement of healthcare in the region. In 2023, the group joined forces with the UK’s Open Medical to incorporate digital transformation solutions in KSA.

Rank: 20
Name: Sherine Helmy
Designation: CEO
Company: Pharco Pharmaceuticals
Country: Egypt

Benefiting from over four decades of pharmaceutical expertise, Helmy actively contributes to various esteemed organisations and holds key positions such as a member of the board of trustees for Egypt-Japan University of Science and Technology.

Additionally, his memberships in organisations like the American Chamber of Commerce in Egypt, the German-Arab Chamber of Industry and Commerce, and the Swiss Egyptian Business Association further highlight his commitment to advancing the pharmaceutical sector and driving meaningful change within the industry.

As a visionary leader, his contributions not only strengthen Pharco’s standing as a reputable pharmaceutical enterprise but also make a significant impact on Egypt’s healthcare landscape and its global collaborations.

With a workforce of 8,000 employees, Pharco has evolved into a prominent pharmaceutical enterprise since its establishment in 1983 by Helmy’s father. The company’s global presence extends to the ownership of 11 companies, solidifying its position as a key player in the pharmaceutical industry.

Pharco Pharmaceuticals is the mother company of Pharco Group with eight health care companies operating in the pharmaceutical field for development, manufacturing, marketing, distributing, and exporting of an array of generics and branded generic drugs along with licensed pharmaceutical products. As the largest manufacturer of pharmaceuticals in the MENA region that exports to over 50 countries around the world.

Rank: 21
Name: Ashish Koshy
Designation: CEO
Company: G42 Healthcare
Country: UAE

An entrepreneurial and solutions-driven business leader with a deep commitment to revolutionising healthcare, Koshy has transformed G42 Healthcare by leveraging data and emerging technologies for personalised and preventive healthcare. Under his leadership, G42 has diversified its interests in healthcare technology, pharma, diagnostics, and more. He helped to facilitate the ground-breaking Pan Arab 4Humanity trials and established the region’s dedicated contract research organisation.

Previously, he held senior positions as the deputy general manager for Technology Development and Innovation at Reliance Jio and Technology Planning at Ooredoo.

G42 Healthcare, a leading AI-powered company, is dedicated to developing a world-class healthcare sector in the UAE and beyond. Their focus on comprehensive AI solutions, data harnessing, and emerging technologies aims to unlock personalised and preventive care in the region. Collaborating with governments, international entities, scientists, researchers, and the medical community, G42 pioneer advancements to safeguard the health of nations worldwide.

Notable achievements include establishing Biogenix Labs, the UAE’s first Covid-19 accredited large-scale throughput laboratory and pioneering the region’s first dedicated contract research organisation (IROS). The company also actively support the national vaccination programme and the Emirati Genome Programme.

Rank: 23
Name: Mohammed Hassan Amin
Designation: Co-founder and Group CEO
Company: Elaj Group
Country: KSA

Dr. Amin is an accomplished healthcare entrepreneur and leader, boasting a distinguished career spanning over two decades. Through his expertise and dedication, he has made significant contributions to advancing healthcare services and ensuring seamless delivery of care in the region. Co-founding Elaj Group in 1994 alongside Mohammed Fawaz Al Bishri, Dr. Amin initially focused on a chronic care delivery model, which later evolved into an integrated healthcare system across the MENA region.

With a strong presence in KSA, Egypt, Qatar, and Oman, Elaj Group operates medical centres and tertiary care hospitals specialising in various treatments, including andrology, infertility, urology, and dermatology. In addition to his position at Elaj Group, Dr. Amin is the visionary founder behind Al Borg Laboratories, a pioneering private laboratory network established in the early 2000s. This network has established a significant presence in the GCC and select African countries, conducting a volume of over 9 million tests.

He spearheads the leadership of SHIC and Tawasul Holding, serving as the regional arms of the group. Guided by his strategic acumen, Tawasul Holding achieved success in leading a pre-Series A funding round for ‘At Home Doc,’ a healthcare venture based in Qatar and secured $1.9 million in funding, a testament to Dr. Amin’s adept leadership and dedication to driving transformative investments in the region’s healthcare sector.

Rank: 24
Name: Ismail Shehada
Designation: CEO, Pharma sector
Company: Saudi Chemical Company Holding
Country: KSA

Backed by a wealth of experience spanning over two decades, Shehada’s career trajectory began in 1999 as a medical representative with GlaxoSmithKline (GSK), where he eventually achieved the position of KSA country manager in 2016. Following this, he assumed the role of general manager at AstraZeneca KSA for two years before advancing to become the area head for the GCC countries and Pakistan, based in Dubai.

In July 2020, Shehada joined Saudi Chemical Company Holding as the CEO of its pharmaceutical business. In this capacity, he oversees three pharmaceutical companies, including Saudi International Trading Company, AJA Pharma, and Chemical Commercial Investment Company Ltd. The holding company boasts assets of $1.3 billion and achieved $699 million in sales during the first nine months of 2022.

The holding company has established prominent CMO deals with companies such as GSK, Abbott, Servier, Lundbeck, and Aspen. Saudi Chemical Company Holding, an investment firm with a $225 million capital, owns a group of five specialised companies in the distribution and manufacture of medicine, pharmaceutical products, medical materials, and equipment.

One of its subsidiaries, AJA Pharma focuses on manufacturing and marketing products in KSA and the GCC through collaborations. Sitco Pharma is dedicated to product distribution in KSA, and the group’s Chemical Commercial Investment Company Ltd. (CCCI) engages in the wholesale and retail trade of medicines, medical materials, and medical equipment.

Rank: 25
Name: Zaid S. Al Khayyat
Designation: Managing director
Company: Al Khayyat Investments (AKI)
Country: UAE

With 13 years of industry experience, Al Khayyat leads his family business, established in the UAE in 1982 by Saad Al Khayyat. He plays a crucial role in driving AKI’s growth and transformation within the MENA region and fosters a culture of excellence and innovation.
He holds a Bachelor of Arts in Management from Suffolk University- Sawyer Business School in Boston, USA.

The company’s primary focus is on the sale and distribution of pharmaceutical and medical products. Through strategic partnerships with patient support providers like AXIOS and IQVIA, the group enhances its services and offerings. AKI operates three healthcare subsidiaries, namely, AKI MedLab, AKI Pharma, and BinSina Pharmacy, each contributing to the group’s success and growth in the healthcare sector.

AKI, a leading family-owned company, is dedicated to delivering high-quality products and adhering to best business practices in all its endeavours. Operating across a diverse portfolio, its partnerships have a positive impact on people’s lives.

Today, AKI’s exceptional products and services extend across nine countries in the region, including the UAE, KSA, Qatar, Bahrain, Kuwait, Oman, Egypt, Jordan, as well as Iraq. Backed by four decades of success, the company’s expertise spans eight business units under six industries, covering retail, healthcare, consumer goods, fitness and lifestyle, contracting, and automotive. Among UAE distributors, AKI Pharma ranks in the top three, and is poised for continued success as one of the region’s most prominent family-owned businesses.

Rank: 26
Name: Amin Magrabi
Designation: Chairman
Company: Magrabi Hospitals and Centres
Country: KSA

In January 2023, Magrabi assumed the role of Chairman at MAGRABi Retail Group, a prominent optical retailer in the Middle East. Before his appointment as chairman, he served as the CEO of MAGRABi Group. His career began in financial services and later led him to join MAGRABi in 2002. With dedication and expertise, he climbed the ranks to become the CEO in 2008.

Apart from his role in MAGRABi Retail Group, he holds several director and executive positions in various organisations, including Magrabi Hospitals and Centres, Al Amin Medical Instruments Co. (AMICO Group), IKEA Saudi and Bahrain, Magrabi Foundation, Africa Eye Foundation, and ARP Global Capital. Since its establishment in 1955, Magrabi Hospitals & Centres has served over one million patients and performed more than 100,000 sight-preserving surgeries annually.

The company’s commitment to innovation is evident in its notable achievements, such as conducting the first corneal transplant surgery in the Middle East in 1968 and introducing the principle of sub-specialisation in ophthalmology. With a network of 32 hospitals across KSA, the UAE, Qatar, Egypt, and Yemen, Magrabi Hospitals & Centres specialise in providing optic and dental care. Their strategic expansion in the late 1970s, which included the acquisition of ENT and dentistry practices, further solidified their position as a regional leader in healthcare. Magrabi Hospitals & Centres recently announced plans for a new surgical tower in Jeddah, scheduled to commence operations in 2024.

Rank: 28
Name: Lennaert Rijken
Designation: Regional vice president Middle East, Africa and Russia
Company: AbbVie
Country: UAE

With a tenure of just over 11 years at AbbVie, Rijken has been in his current role since March 2022 and is based in Dubai, UAE. He initially joined the group in the role of business unit director immunology from July 2012 to February 2015, and continued to climb the ranks, working as the senior commercial director, Western Europe and Canada for two years to general manager Netherlands for five years.

Prior to his tenure at AbbVie, Rijken served for six years at Abbott Laboratories across various roles, including commercial director Asia/Australia/Africa/Middle East for one year; the business unit director immunology in China for one year, among others. As part of the company’s leadership team, Rijken oversees a workforce of 1,200 professionals operating across the MEA and Russia.

AbbVie is a renowned biopharmaceutical company, publicly traded, and established in 2013 as a distinct entity from Abbott. In a significant development in October 2022, AbbVie formed a strategic collaboration with the Department of Health in Abu Dhabi to advance manufacturing capabilities and conduct clinical research in the region. This partnership aims to contribute to the advancement of medical innovation and the improvement of healthcare outcomes for patients in the UAE and beyond.

AbbVie has a footprint in over 70 countries with over 50,000 employees. The company boasts more than 250 partnerships with leading biotechs, universities, non-profits, and government organisations.

Rank: 29
Name: Basel Ziyadeh
Designation: CEO
Company: Julphar
Country: UAE

With over 25 years of experience in the pharmaceutical industry, Ziyadeh has worked with top global and regional companies across the MENA region, gaining expertise in pharmaceutical marketing, multi-site manufacturing, strategy development in vaccines, biological medicines, and business development and distribution.

His leadership journey includes serving as the CEO for Tabuk Pharmaceuticals, where he played a key role in transforming the business and significantly expanding profitability, along with establishing key partnerships.

Previously, he held several leadership positions at Hikma Pharmaceuticals over a 15-year period during which he led the company’s branded strategy formulation and execution in the MENA region and managed their operations in the GCC and the Levant. Additionally, he served as an advisor and board member for several pharmaceutical entities in KSA, Egypt, Jordan, Sudan, Iraq, and Lebanon.

Julphar, established in 1980 under the guidance of Sheikh Saqr Bin Mohammed Al Qasimi, is a pharmaceutical manufacturer in the Middle East and Africa. With a focus on delivering high-quality, innovative, and affordable healthcare solutions, they have become one of the world’s top producers of insulin.

Their business centres around Julphar Diabetes Solutions, general medicines, and their consumer division, offering a wide range of medicines targeting various therapeutic segments. With a team of 2,500 professionals, Julphar distribute their products to over 50 countries on five continents.

Rank: 30
Name: Jean-Paul Scheuer
Designation: General manager specialty care, MCO Lead Greater Gulf
Company: Sanofi
Country: UAE

Backed by over 20 years of experience in the pharmaceutical industry, Jean-Paul currently leads around 700 people at Sanofi, where he has been for over 14 years. Under his guidance, Sanofi achieved growth with a 37 percent increase in sales in 2022 compared to 2021.

He previously served as the country chair and general manager RX for Sanofi Gulf and Yemen as well as the general manager in Ukraine for 12 years. Prior to joining Sanofi, he held various positions at Servier for seven years, including general manager roles in Austria and Ukraine.

Sanofi, a global pharmaceutical company, has been operating in the Gulf since the 1970s and established its first affiliate in the UAE in 1987. The Greater Gulf region stands as one of Sanofi’s top eight markets, and today, the company focuses on health solutions for diabetes, cardiovascular diseases, oncology, immunology, multiple sclerosis, and vaccines.

In 2019, Sanofi opened a state-of-the-art logistics centre in the UAE, enabling efficient medicine delivery to six regional countries. Recently, Sanofi signed a collaboration agreement with Abu Dhabi Health Services Company (SEHA) to support rare disease patients in the UAE, aiming to enhance medical practices and provide better health outcomes.

This partnership is expected to foster innovation and sustainable capabilities. By shortening the diagnosis journey and ensuring timely care, the collaboration aims to improve patient outcomes and enhance their overall quality of life.

Rank: 31
Name: Jobilal Vavachan
Designation: CEO
Company: Life Healthcare Group
Country: UAE

Aqualified pharmacist by profession, Vavachan embarked on his pharmaceutical career in India and then later relocated to the UAE in 1996. In 2005, he joined DM Healthcare in the role of senior manager, operations for the pharmacy division. Under his guidance, the pharmacy division experienced an upward trajectory in its network.

He currently serves as the CEO of Life Pharmacy, a position he assumed in June 2021. Prior to his role at Life Pharmacy, he held the position of CEO at Aster Pharmacy for eight years. During his tenure at Aster Pharmacy, he exhibited strong leadership, driving the growth of the pharmacy network and spearheading business expansion through innovative green field projects.

Founded by Abdul Nazar in 1996, Life Pharmacy started out as a retail pharmacy group and since then, has grown to become the largest pharmacy network in the UAE, boasting 375 pharmacies, healthcare hypermarkets, as well as health and wellness stores across the country. The company caters to an average of 10 million customer walk-ins annually and operates an online pharmacy in the UAE. The company’s focus is on expansion, with plans to reach 1,500 stores by the end of 2025, strategically located in business districts.

Life employs over 3000 professionals and has introduced innovative concepts in the region, such as the first Healthcare Hypermarket in the GCC and the first Drive-Thru pharmacy in the Middle East.

Rank: 32
Name: Tamer El Sallab
Designation: Head of Gulf and Levant Cluster
Company: Viatris
Country: UAE

An accomplished professional with over 15 years of experience in the pharmaceutical industry, El-Sallab boasts a diverse career spanning over a decade in the pharmaceutical industry. In his current role since March 2021, he is responsible for leading operations in the region. Before joining Viatris, he served as the country lead at Pfizer from December 2018 to November 2020, where he successfully led the UAE business in the Pfizer Essential Health Division.

Prior to his tenure at Pfizer, El-Sallab held various leadership roles at Novartis, including as the head of sales from June 2015 to November 2016 and cardiovascular and metabolic franchise line manager from September 2013 to May 2015. During his time at Novartis, he was instrumental in building strong business relationships with top medical experts in the field.

Established in November 2020, Viatris is the result of the merger between Pfizer’s Upjohn unit and Mylan, and their portfolio includes globally recognised brands, complex generics, branded medicines, and an array of over-the-counter consumer products. With a global team of approximately 37,000 colleagues, Viatris supports innovative approaches to CME programmes while collaborations include partnerships with government entities such as the UAE Ministry of Health and Prevention and the Ministry of Health in Oman. Additionally, Viatris works closely with universities and academia, including New York University Abu Dhabi and the American College of Cardiology.

Rank: 33
Name: John Ireland
Designation: Acting CEO and CFO
Company: Amanat Holdings
Country: UAE

Backed by a wealth of experience and expertise, throughout Ireland’s career, he has held significant leadership roles in finance, strategy, and business development across diverse industries like real estate, media, and entertainment. Prior to his appointment at Amanat, Ireland held the position of CFO for several prominent listed and private organisations, both locally and internationally.

His extensive experience in financial management and strategic planning has been pivotal in driving growth and success for these companies. He earned a Bachelor of Arts degree in Business Management from the University of Exeter. And as a qualified chartered accountant, Ireland’s proficiency in financial analysis and accounting principles helps bolster the company’s sustained growth in today’s business landscape.

Amanat Holdings is a strategic investor in the healthcare and education sectors. Their healthcare platform consists of five specialised hospitals, providing a total of around 450 beds distributed across the UAE, KSA, and Bahrain. In terms of financial performance, their healthcare platform achieved a robust $91 million in revenues in 2022.

This revenue figure represents the total income generated by the healthcare platform during that year, indicating a significant success in the healthcare industry across the three countries. By investing in healthcare and education and establishing specialised hospitals, Amanat is strategically positioning itself to capitalise on the growth potential in these sectors.

Rank: 34
Name: Ole Per Maloy
Designation: Managing director; Middle East, Southern and Eastern Africa
Company: Siemens Healthineers
Country: UAE

Ole Per Maloy was appointed to his current role in January 2018, and prior to assuming this position, he held several key leadership roles within Siemens Healthineers, including serving as the General Manager and Senior Vice President (SVP) for Western Europe and Western Africa. His career progression and extensive experience within the company highlight his significant contributions to its growth and success.

For over 125 years, Siemens Healthineers have been at the forefront of pushing the boundaries in medical technology with innovations that include cutting-edge advancements in imaging, diagnostics, and cancer therapy.

In the financial year of 2022, Siemens Healthineers achieved revenues of $6 billion from its operations in the EMEA region, excluding Germany and reflects the company’s strong presence and success in providing innovative healthcare solutions to a wide range of customers across the EMEA region.

The achievement of such significant revenues underscores Siemens Healthineers’ position as a key player in the healthcare industry and highlights its ability to meet the diverse needs of healthcare providers and patients in the region.

At Siemens Healthineers, their mission is to enable healthcare providers to increase their value by equipping them with innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine, as well as digital health and enterprise services.

Rank: 35
Name: Akram Bouchenaki
Designation: CEO
Company: Abdul Latif Jameel Health
Country: KSA

Bouchenaki has accumulated 25 years of valuable experience in various operational and strategic roles within the pharmaceutical and healthcare sectors. Prior to his current role, he served as the executive director for Africa at Gilead Sciences, a prominent pharmaceutical company.

He has also held key positions at large pharmaceutical companies including GSK and Bristol Myers Squibb, and boasts a diverse background in various healthcare organisations. With his robust leadership experience, Bouchenaki is well-positioned to contribute significantly to the growth and success of Abdul Latif Jameel Health as the company continues to expand its presence in the healthcare sector.

Abdul Latif Jameel Health operates as part of Abdul Latif Jameel, a group of independent and international, family-owned, and diversified businesses that was founded in 1945 by the late Abdul Latif Jameel. Abdul Latif Jameel Health was established in 2020 and today, is backed by a multi-sector presence in 30 countries across six continents.

In January 2023, Abdul Latif Jameel Health made a significant announcement regarding a new distribution agreement with iSono Health, a US-based medical technology company. As part of this agreement, Abdul Latif Jameel Health is granted the exclusive distribution rights for iSono Health’s ATUSA scanner in the MENA region, Africa, South Asia, and Southeast Asia.

Rank: 36
Name: Alexander Jankuloski
Designation: CEO
Company: Kuwait Hospital
Country: Kuwait

In July 2020, Jankuloski assumed the leadership position at Kuwait Hospital. With an extensive background of 14 years in various managerial roles within the hospital industry, his appointment brought a wealth of expertise and vision to the institution. Before joining Kuwait Hospital, he held the position of CEO at Oasis Hospital, now recognised as Kanad Hospital.

Kuwait Hospital, founded in 2005, achieved a considerable milestone in 2019 when the Swedish healthcare provider GHP took over the hospital’s operations. This further solidified Kuwait Hospital’s commitment to achieving excellence in patient care. The collaboration brings forth unparalleled resources, expertise, and innovation, allowing the hospital to elevate its standards of medical treatment and patient experience, further enhancing its reputation for quality medical services.

As Kuwait Hospital continues to grow and evolve under the guidance of Jankuloski as well as the support of GHP, it remains firmly devoted to its mission of delivering exceptional healthcare services to the community it serves.

Kuwait Hospital is a distinguished private multi-speciality facility that takes pride in offering a wide range of premium healthcare services to patients. With its state-of-the-art medical equipment and a team of highly skilled professionals, the hospital is committed to providing excellent care across various specialties.

Rank: 37
Name: Hasan Al Nowais
Designation: CEO
Company: Mubadala Health
Country: UAE

Mubadala Health’s network of hospitals, laboratories, and health centres, along with more than 11,000 people, is helmed by Hasan Jasem Al Nowais. Prior to the launch of Mubadala Health, he was a key force behind the healthcare platform within Mubadala Investment Company (MIC) which he joined in 2007.

Here, Al Nowais was responsible for overseeing international hospitality projects across the US, the Middle East, and other parts of Asia, including brands such as Viceroy, Four Seasons, and Rosewood.

He also previously held the role of chief administrative officer of Cleveland Clinic Abu Dhabi. He is also the vice chairman of Cleveland Clinic Abu Dhabi, chairman of the Rosewood Abu Dhabi and the Four Seasons Hotel Abu Dhabi, as well as serves as a board member of the Viceroy Hotel Group. He is also on the board of Yas Holding, chairman of Yas Holding Healthcare Committee, and a member of the Miral Audit Committee.

In 2021, Mubadala Health was established as an integrated network of world-class healthcare providers with the vision to drive sustainable development and growth in the UAE and beyond. The organisation operates, manages, and develops a diverse portfolio of healthcare assets, which includes Cleveland Clinic Abu Dhabi, Healthpoint, Imperial College London Diabetes Centre (ICLDC), Amana Healthcare, National Reference Laboratory (NRL), Capital Health Screening Centre (CHSC), Abu Dhabi Telemedicine Centre (ADTC), Moorfields Eye Hospital Abu Dhabi, and several others.

Rank: 38
Name: Dr. Bashar Bizrah
Designation: Consultant, MD, FRCS Special Expertise in Nose Reshaping and Facial Plastic Surgery
Company: Bizrahmed
Country: UAE

Dr. Bizrah is an accomplished rhinoplasty surgeon, known for his significant contributions to the field. He has performed over 38,000 rhinoplasty procedures with over 7,000 Dubai cosmetic surgeries on international patients since 2016. He has founded two clinics, one in Dubai and one in London, and has authored a textbook on facial cosmetic surgery. The clinic, Bizrahmed, operates branches in both London and Dubai, where it offers a comprehensive range of medical and cosmetic surgeries, utilising cutting-edge technology to achieve the highest level of patient care.

His innovative techniques have brought advancements to rhinoplasty, facelifts, and blepharoplasty. Dr. Bizrah’s unique and inclusive approach sets him apart in the field of cosmetic surgery as he has consistently demonstrated his awareness of the importance of customising procedures to suit each patient’s background and ethnicity. His diverse patient base is comprised of patients from Europe, the Middle East, India, Africa, and China.

His clinics prioritise adhering to the highest international standards and the medical team comprises of highly skilled and professional doctors who are well-experienced in their respective fields. His expertise has earned him a position among the world’s top 10 influential rhinoplasty surgeons and his accomplishments in the field have garnered widespread recognition.

Rank: 39
Name: Dr. Rami Abadi
Designation: General and cosmetic dermatologist and founder
Company: Dr. Rami Abadi Clinic
Country: Lebanon

Akey industry leader specialised in general and cosmetic dermatology, in 2007, Dr. Abadi obtained his medical degree from the American University of Beirut (AUB) Faculty of Medicine. He later went on to obtain a Fellowship in Cosmetic Dermatology at the Baumann Cosmetic and Research Institute in the US and since 2015, holds an MBA from the Lebanese American University (LAU).

Boasting over a decade of expertise, as a testament to his skill and knowledge, Dr. Abadi holds prestigious roles as a local country mentor for Allergan and a regional trainer for Silhouette Soft Threads and Cutera. His passion for sharing knowledge and advancements in the industry is evident through his active involvement in giving presentations and conducting workshops on Restylane and Emervel, two prominent soft tissue fillers, across the region.

Through his Dr. Rami Abadi Clinic, he provides cutting-edge nutrition services as well as skincare services that range from facial and body therapies for rejuvenation and anti-aging as well as aesthetic treatments, with expertise in minor surgical procedures, thread lifting, minimally invasive cosmetic procedures, and laser treatments.

He works with his patients to develop the best treatment approach that is personalised to a specific condition or concerns. The clinic also offers medical dermatology, cosmetic dermatology, face and neck treatments, and body treatments. Dr. Abadi’s practice includes a team of medical assistants, licensed technicians, and clinical dietitian to provide the highest quality care.

Rank: 40
Name: Dr. Sanjay Parashar
Designation: Chairman and plastic surgeon
Company: Cocoona Centres
Country: UAE

Since his arrival to Dubai in 2005, Dr. Parashar has harboured a dream to make Dubai the Beverly Hills of the Middle East. Endowed with several skills including sculpting, art, and ambidexterity, he has travelled globally to work in leading institutes in the US, South Korea, Bahrain, and Australia.

Through his work with globally renowned plastic surgeons, including Prof. David David, and Dr. Tony Moore, Prof. Lan Jackson, to name a few, Dr. Parashar further refined his skills across laser surgery, craniofacial surgery, and aesthetic surgery.

Backed by three decades of experience in the plastic surgery industry, he has performed over 15,000 surgeries, spanning across liposuction, breast augmentation, breast reductions, breast lift, face lift, rhinoplasty, tummy tuck and more.

As of April 2023, Cocoona is gearing up for major regional expansion, after initial talks to raise over $30 million from new investors. The long-term growth strategy in the pipeline will witness further expansion in the UAE in addition to the launch of new centres in KSA, India, and Kuwait.

He has authored two books, contributed in some books, and has written a host of medical papers. He chairs the scientific committee of Emirates Plastic Surgery society; is the National Secretary of International Society of Aesthetic Plastic Surgery (ISAPS); and is also the president of FUE Asia. He also helms Beverly Hills Plastic Surgeons by Cocoona, a medical software and IT Company; SkinbyCocoona; and Salon 900 by Cocoona.